α tubulin and β actin antibodies

The following primary antibodies were used: α-synuclein monoclonal antibody (BD Biosciences), γH2AX, phospho-ATM, ATM, p53, H3, poly(ADP-ribose) polymerase (PARP), ERCC1, XRCC1, MRE11, Rad51, Ku80, DDB2, p16, p73, and H3K9me3 antibodies (Abcam, Cambridge, UK); H2AX, phospho-p53, p21, and Ku70 antibodies (Cell Signaling Technology, Danvers, MA, USA); α-tubulin and β-actin antibodies (Sigma–Aldrich Corp., St. Louis, MO, USA); and 53BP1 antibody (Novus Biologicals, Centennial, CO, USA).
Retinoic acid, poly-L-lysine, and glutathione were obtained from Sigma–Aldrich. NE-PER™ Nuclear and Cytoplasmic Extraction Reagents were obtained from Thermo Fisher Scientific (Waltham, MA, USA). X-gal was obtained from Duchefa Biochemie (Haarlem, Netherlands).

Antibodies against EGFR, BRD4, p-ERK1/2, p53 and Rad51 were purchased from Cell Signaling Technology, catalogue numbers 4267, 13440, 9101, 48818 and 8875, respectively. Antibody against p63 was from Santa Cruz Biotechnology (sc-8431). P73 antibody was from Abcam (ab26123). Antibody against p16INK4a was purchased from ThermoFisher (MA5-17054). α-tubulin and β-actin antibodies were from Sigma, catalogue numbers T6074 and A5441, respectively. Selumetinib was purchased from Selleck (S1008). BRD4 inhibitor MZ1 was purchased from Abcam (ab230371).